BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka [1 ]
Joyner, Kayla [2 ]
Reid, Nancy [1 ]
机构：
[1] Winchester Med Ctr, Winchester, VA USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Winchester, VA USA
来源：
CRITICAL CARE MEDICINE | 2023年 / 51卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
409
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [11] Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
    Bryushkova, Ekaterina A.
    Skatova, Valeria D.
    Mutovina, Zinaida Y.
    Zagrebneva, Alena, I
    Fomina, Daria S.
    Kruglova, Tatyana S.
    Akopyan, Anna A.
    Strazhesko, Irina D.
    Lukyanov, Sergey A.
    Tkacheva, Olga N.
    Lysenko, Maryana A.
    Chudakov, Dmitry M.
    PLOS ONE, 2022, 17 (08):
  • [12] Tocilizumab in severe COVID-19
    Liberato, Nicola Lucia
    De Monte, Andrea
    Caravella, Giuseppe
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1457 - 1458
  • [13] Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
    Foo, Hong
    Phan, Fiona
    Bagatella, Melissa
    Petrovski, Irene
    Nagendra, Vana
    Acharya, Priya
    Levy, Miriam
    Prakoso, Emilia
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (06) : 799 - 801
  • [14] Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
    Hong Foo
    Fiona Phan
    Melissa Bagatella
    Irene Petrovski
    Vana Nagendra
    Priya Acharya
    Miriam Levy
    Emilia Prakoso
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 799 - 801
  • [15] Risk of hepatitis B reactivation following treatment with baricitinib or tocilizumab for COVID-19
    Foo, H.
    Phan, F.
    Bagatella, M.
    Acharya, P.
    Petrovski, I.
    Nagendra, V.
    Levy, M.
    Prakoso, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 71 - 72
  • [16] Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
    Gavriilidis, Efstratios
    Antoniadou, Christina
    Chrysanthopoulou, Akrivi
    Ntinopoulou, Maria
    Smyrlis, Andreas
    Fotiadou, Iliana
    Zioga, Nikoleta
    Kogias, Dionysios
    Natsi, Anastasia-Maria
    Pelekoudas, Christos
    Satiridou, Evangelia
    Bakola, Stefania-Aspasia
    Papagoras, Charalampos
    Mitroulis, Ioannis
    Peichamperis, Paschalis
    Mikroulis, Dimitrios
    Papadopoulos, Vasileios
    Skendros, Panagiotis
    Ritis, Konstantinos
    CLINICAL IMMUNOLOGY, 2022, 238
  • [17] Effective treatment of severe COVID-19 patients with tocilizumab
    Xu, Xiaoling
    Han, Mingfeng
    Li, Tiantian
    Sun, Wei
    Wang, Dongsheng
    Fu, Binqing
    Zhou, Yonggang
    Zheng, Xiaohu
    Yang, Yun
    Li, Xiuyong
    Zhang, Xiaohua
    Pan, Aijun
    Wei, Haiming
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (20) : 10970 - 10975
  • [18] Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
    Wang, Yong
    Chen, Yongfeng
    Zhou, Xiangdong
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2022, 2022
  • [19] Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study
    You, Seung-Hun
    Baek, Moon Seong
    Kim, Tae Wan
    Jung, Sun-Young
    Kim, Won-Young
    CRITICAL CARE, 2024, 28 (01)
  • [20] Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study
    Conroy, Grace M.
    Bauer, Seth R.
    Pallotta, Andrea M.
    Duggal, Abhijit
    Wang, Lu
    Sacha, Gretchen L.
    PHARMACOTHERAPY, 2024, 44 (01): : 28 - 38
12345